Doctronic.
The AI doctor is in.

An AI that answers first, and bills you $39 only if you want a human

Here is a fact about American healthcare that Doctronic likes to repeat, because it is both true and slightly absurd: the average wait to see a doctor is about three weeks. Three weeks is a long time to wonder whether the rash is nothing or something. Doctronic's whole business is built on collapsing that number to roughly zero for the first question, and to about thirty minutes for the second.

The way it works is deceptively simple. You open Doctronic, you describe what is wrong, and you don't make an account, you don't hand over insurance, you don't even give your name. The AI - trained by physicians and, the company says, cross-checked against thousands of custom clinical guidelines - gives you an assessment and a treatment plan. That part is free. If you want a real, licensed human on video, that's $39, or an insurance copay, and Doctronic says it can put one in front of you in about half an hour, in any of the 50 states. Prescription refills start at $0.

This is a tidy funnel, and funnels are usually where the skepticism starts. But the interesting thing about Doctronic is not the pricing. It's that the company has spent two years arguing - with regulators, with doctors, and implicitly with everyone who finds the phrase "AI doctor" alarming - that the AI is not just a fancy search box in front of the human. It is, they insist, doing medicine.

Two founders, two grievances

Doctronic was founded in 2023 by two people with complementary complaints about healthcare. Matt Pavelle is the technologist - a serial founder with 25 years of building behind him, including a stint as founding CTO of the fashion unicorn Moda Operandi. His origin story, per the company, involves a personal experience with a delayed diagnosis, the kind of thing that turns a healthy annoyance with the system into a startup.

Dr. Adam Oskowitz is the clinician - a practicing vascular surgeon and associate professor at UCSF, with more than two decades at top medical institutions. His grievance is the one you hear from a lot of doctors: too little time, too many patients, tools that feel a decade out of date. Put the two frustrations together and you get the Doctronic thesis, which is that a well-built AI can absorb the routine volume that burns physicians out, and physicians can handle what actually needs a physician.

The agents that argue with each other

Under the hood, Doctronic describes something it calls a "micro-agentic consensus" architecture. Rather than a single model confidently spitting out an answer - the failure mode everyone worries about with medical chatbots - Doctronic runs multiple specialized AI agents that challenge each other's conclusions before anything reaches the patient. The company claims this produces a 99.2% alignment with board-certified clinicians on treatment plans in its own published research. That number deserves the usual caveat - it's the company's own study - but the design instinct is the right one. In high-stakes AI, you want the machine to disagree with itself before it agrees with you.

Doctronic also makes a promise that is easy to make and hard to keep in this industry: it says it does not train its models on users' medical conversations. In a business where patient data is usually the point, choosing not to hoard it is a genuine decision, and the company treats it as a feature - HIPAA compliance, end-to-end encryption, anonymous chats by default.

The Utah moment

In January 2026, Doctronic did the thing that got everyone's attention. Under Utah's "AI Learning Lab" regulatory sandbox, it became the first AI-native platform allowed to autonomously and legally renew prescriptions in the United States - specifically, routine refills for patients with chronic conditions. This is a genuinely novel regulatory event. For all the talk about AI in medicine, the wall has always been that an AI could suggest, but a licensed human had to sign. Utah moved that wall, at least a little.

Predictably, not everyone was delighted. The move drew a heated debate among clinicians and health-policy watchers about what "autonomous medical practice" should mean, and where the human belongs in the loop. That debate is worth having, and Doctronic - to its credit or its convenience, depending on your view - is now the concrete example everyone argues about. Being the test case is a form of leadership, and also a form of risk.

The money, and the speed of it

Investors, at least, are comfortable with the risk. Doctronic raised roughly $5M in seed funding led by Union Square Ventures, then a $20M Series A led by Lightspeed Venture Partners, and in March 2026 a $40M Series B co-led by Abstract and Lightspeed. That's $65 million across three rounds in under a year, with a cap table that includes Tusk Ventures, Seven Stars, Mantis, and angels like Stanford AI luminary Fei-Fei Li. The company reports growing roughly 15x to an eight-figure annualized revenue run rate in the months after the Series A.

What's next is the boring, expensive part of healthcare: expansion. Doctronic says it will move into pediatrics and pursue partnerships with academic institutions, payers, digital health platforms, and hospital systems. The long-term bet, stated plainly by the company, is that the majority of primary care can eventually be delivered by AI - accessible to anyone, anywhere, anytime, with humans supervising and stepping in. It's an enormous claim. The interesting part is that, for the first time, there's a regulator, a revenue line, and 300,000 weekly users to argue about it with.